United States Cancer Genomic Testing Market was valued at USD 4.8 Billion in 2022 and is projected to reach USD 10.2 Billion by 2030, growing at a CAGR of 10.0% from 2024 to 2030.
The US Cancer Genomic Testing Market is rapidly evolving as the demand for personalized treatment options and precision medicine increases. The ability to analyze a patient's genetic makeup and identify specific mutations that drive cancer has revolutionized the way we approach cancer treatment. This market is driven by innovations in technology, increasing prevalence of cancer, and rising awareness among healthcare professionals and patients. Genomic testing allows for tailored treatments that are more effective and less toxic, offering patients better outcomes and a higher quality of life.
Among the key types of cancer genomic tests, the two most prominent include next-generation sequencing (NGS) and polymerase chain reaction (PCR) tests. NGS provides a comprehensive view of genetic mutations by sequencing large portions of DNA, while PCR focuses on detecting specific genetic sequences. Both methods are widely adopted for their ability to identify genetic abnormalities linked to various cancer types, including breast, lung, and colorectal cancers. The adoption of these tests has been spurred by technological advancements that make these tests more accurate and affordable.
Industries are increasingly turning to cancer genomic testing as it enhances their understanding of disease pathways and helps in the development of novel therapeutics. Pharmaceutical companies are leveraging genomic testing to identify potential biomarkers for targeted therapies. This, in turn, aids in the discovery of more effective drugs that can target specific cancer mutations, reducing side effects and improving patient outcomes. Moreover, diagnostic laboratories and healthcare providers are expanding their use of genomic testing to support early detection and personalized treatment plans, driving market growth.
The need for cancer genomic testing is also growing in the research sector. Institutions and biotech companies are investing heavily in the study of genetic mutations associated with cancer to improve screening methods, create better risk models, and understand cancer's molecular drivers. As more data becomes available, the market for cancer genomic testing is expected to continue expanding, with new applications emerging in both clinical and research settings.
In conclusion, the US Cancer Genomic Testing Market is undergoing significant transformation, driven by advancements in technology, the increasing demand for precision medicine, and a growing recognition of the value of personalized treatment approaches. As genomic testing becomes more integrated into cancer care, industries across the board are increasingly reliant on these innovative technologies to improve patient outcomes and fuel future cancer research and drug development.
Get an In-Depth Research Analysis of the US Cancer Genomic Testing Market Size And Forecast [2025-2032]
Â
Myriad Genetics
Centogene AG
Color Genomics
Quest Diagnostics
23andMe Inc.
Gene By Gene Ltd.
LabCorp
Positive Bioscience
Bio-Rad Laboratories
Illumina
Inc.
Agilent Technologies
Thermo Fisher Scientific
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Cancer Genomic Testing Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Cancer Genomic Testing Market
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescent In Situ Hybridization (FISH)
Microarray Analysis
Other Genomic Testing Methods
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia
Other Cancers
Tissue Biopsies
Blood Sample-Based Testing
Urine-Based Tests
Saliva Tests
Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies
Risk Assessment
Patient Stratification
Therapeutic Decision Making
Monitoring Treatment Response
Recurrence and Progression Monitoring
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Cancer Genomic Testing Market Research Analysis
1. Introduction of the US Cancer Genomic Testing Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Cancer Genomic Testing Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Cancer Genomic Testing Market, By Type
6. US Cancer Genomic Testing Market, By Application
7. US Cancer Genomic Testing Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Cancer Genomic Testing Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/